Probiotics in Pulmonary Fibrosis: What Does the Evidence Actually Show?

Can Probiotics Help Pulmonary Fibrosis?

Interest in probiotics has expanded far beyond digestive health.

Researchers are now investigating whether microorganisms living in the intestine can influence organs located far from the gastrointestinal tract—including the lungs.

This communication network is known as the gut–lung axis.

Pulmonary fibrosis has recently become an important area of gut–lung research.

Studies have identified changes in the intestinal microbiome in pulmonary fibrosis, while experimental research suggests that microbial metabolites can influence:

• immune regulation

• intestinal barrier integrity

• epithelial injury

• fibroblast activation

• autophagy

• fibrotic signaling

This naturally raises an important question:

Could probiotics modify the gut microbiome in a way that helps pulmonary fibrosis?

The answer is scientifically interesting but clinically cautious.

Experimental studies suggest that selected probiotic organisms can reduce lung inflammation and fibrosis in animal models.

A particularly interesting 2025 study found that a strain of Lactiplantibacillus reduced bleomycin-induced pulmonary fibrosis in mice, modified the gut microbiome and increased a circulating metabolite linked with suppression of TGF-β-related fibrotic signaling. (PubMed⁠)

However:

There is currently no probiotic proven in human clinical trials to stop, reverse or reliably slow idiopathic pulmonary fibrosis.

That distinction should guide both conventional and integrative approaches.

What Are Probiotics?

Probiotics are live microorganisms that, when administered in adequate amounts, may provide a health benefit.

Common probiotic groups include species belonging to:

• Lactobacillus

• Lacticaseibacillus

• Lactiplantibacillus

• Bifidobacterium

• Saccharomyces

But the word “probiotic” can be misleading if used too broadly.

Probiotic effects are generally:

strain-specific.

A benefit demonstrated with one strain cannot automatically be attributed to another organism from the same genus.

For example, a study showing an effect from one Lactiplantibacillus strain does not prove that every Lactobacillus-containing supplement will produce the same result.

This is particularly important when discussing pulmonary fibrosis, because commercially available probiotic supplements are extremely heterogeneous.

Why Study Probiotics in a Lung Disease?

The rationale comes from the gut–lung axis.

The gut microbiome produces biologically active substances capable of entering systemic circulation.

These include:

• short-chain fatty acids

• tryptophan-derived metabolites

• bile-acid metabolites

• lipid metabolites

• microbial peptides

Gut microorganisms also influence:

• intestinal-barrier integrity

• regulatory T cells

• Th17 cells

• macrophages

• dendritic cells

• inflammatory cytokines

These immune and metabolic signals may influence lung physiology.

A major 2025 review of pulmonary fibrosis identified immune dysregulation, barrier dysfunction, epithelial–mesenchymal signaling, autophagy and microbial peptide-mediated epithelial injury as major potential mechanisms linking microbiota with fibrosis. (PubMed⁠)

A 2026 review further emphasized SCFAs, bile acids, tryptophan metabolites, LPS and TMAO as potential mediators linking the intestinal microbiome with pulmonary fibrosis. (PubMed⁠)

Therefore, researchers are not proposing that probiotics physically travel from the intestine into the lungs.

Instead, probiotics may theoretically alter the microbial ecosystem and its metabolites, which could then influence pulmonary immunity.

Is the Gut Microbiome Actually Altered in Human IPF?

Yes.

One of the strongest human studies was published in 2026.

Investigators analyzed fecal microbiota from 411 patients with idiopathic pulmonary fibrosis enrolled in the CleanUP-IPF trial.

They used 16S sequencing and shotgun metagenomic methods.

Gut microbial composition varied with factors including:

• age

• sex

• proton-pump inhibitor use

More importantly, gut microbiota characteristics were associated with percent predicted DLCO, and selected microbial features were associated with transplant-free survival in certain analyses. (PubMed⁠)

This provides important evidence that intestinal microbial ecology is associated with clinically meaningful features of human IPF.

But it does not demonstrate that giving probiotics improves IPF.

What Happens to the Gut Microbiome in Experimental Pulmonary Fibrosis?

Animal models provide stronger mechanistic evidence.

Bleomycin-induced pulmonary fibrosis can produce substantial alterations in intestinal microbial composition.

A study comparing animals housed under different microbial conditions found that germ-free mice were relatively protected against pulmonary fibrosis.

Mice with different intestinal microbiomes developed different degrees of fibrosis.

Most strikingly, transferring stool from mice with the microbiome associated with more severe fibrosis into germ-free mice transferred a more severe fibrotic phenotype.

The more severe phenotype was associated with increased:

IL-6 → STAT3 → IL-17A signaling. (PubMed⁠)

This experiment provides unusually strong evidence that gut microbiota can modify fibrosis severity—at least in mice.

That is considerably stronger than merely observing dysbiosis.

But mouse fibrosis remains biologically different from human IPF.

The 2025 Lactiplantibacillus LP03 Study

One of the most interesting recent probiotic studies evaluated three strains in a bleomycin pulmonary fibrosis model.

Among them, Lactiplantibacillus sp. LP03 showed the strongest antifibrotic effect.

Researchers reported reductions in:

• mortality

• systemic inflammation

• interstitial thickening

• collagen deposition

• epithelial-to-mesenchymal transition

LP03 also altered intestinal microbial composition.

There was increased abundance of organisms including:

• Ligilactobacillus

• Akkermansia

But perhaps the most interesting finding came from metabolomics.

LP03 increased circulating palmitoylethanolamide, or PEA.

When PEA was administered independently, it also reduced experimental fibrosis.

Mechanistic studies suggested inhibition of:

TGF-β1 → Smad2/3 signaling

and suppression of epithelial-to-mesenchymal transition. (PubMed⁠)

This study illustrates an important emerging concept.

A probiotic may not act simply because it is a “good bacterium.”

It may work by altering the microbial ecosystem and producing downstream metabolic signals.

Does This Mean LP03 Is a Treatment for IPF?

No.

The experiment was performed in a bleomycin mouse model.

It did not demonstrate that LP03:

• improves human FVC

• improves DLCO

• slows HRCT progression

• reduces acute exacerbations

• improves survival

• replaces antifibrotic therapy

The finding identifies a candidate pathway for future research.

It does not establish clinical efficacy.

Probiotics May Work Through Microbial Metabolites

The LP03 study supports a wider principle:

the therapeutic effect may come from what microorganisms produce rather than merely which microorganisms are present.

Potential microbiome-derived mediators include:

• SCFAs

• PEA

• indole metabolites

• bile-acid derivatives

This may ultimately shift the field from conventional probiotics toward postbiotics.

Postbiotics include microbial products or metabolites that may provide biological effects without requiring administration of living organisms.

For pulmonary fibrosis, this may eventually be more predictable than simply administering broad probiotic combinations.

Short-Chain Fatty Acids and Probiotic Effects

Probiotic organisms can potentially alter networks of bacteria involved in production of:

• acetate

• propionate

• butyrate

These short-chain fatty acids influence immune and epithelial biology.

They may act through receptors including:

• GPR41

• GPR43

• GPR109A

and through inhibition of histone deacetylases.

SCFAs can influence:

• regulatory T cells

• macrophages

• intestinal barrier integrity

• cytokine production

A 2025 review highlighted dietary fiber and SCFA production as major components of microbiota-mediated lung immune regulation. (PubMed⁠)

However, increasing probiotic bacteria does not guarantee increased SCFA availability.

SCFA production depends on:

• microbial species

• microbial cross-feeding

• dietary substrates

• intestinal environment

This is why diet and probiotics cannot be considered separately.

Probiotics and the Intestinal Barrier

Another proposed mechanism is improved intestinal-barrier integrity.

Certain probiotics can support:

• tight-junction proteins

• mucus production

• epithelial function

If intestinal permeability decreases, systemic exposure to microbial products such as LPS might also decrease.

A theoretical pathway could therefore be:

Probiotic
↓
improved microbial ecosystem
↓
improved intestinal barrier
↓
reduced microbial translocation
↓
less systemic inflammatory signaling
↓
potential pulmonary benefit

This is biologically plausible.

It remains unproven as a therapeutic pathway in human pulmonary fibrosis.

Probiotics and Treg–Th17 Balance

Gut microorganisms influence differentiation of regulatory T cells and Th17 cells.

Th17 signaling is particularly interesting in pulmonary fibrosis.

Experimental microbiome work has linked more severe fibrosis with greater IL-6/STAT3/IL-17A signaling. (PubMed⁠)

A probiotic that restores microbial balance could theoretically:

• increase regulatory signals

• decrease excessive Th17 activation

• modify macrophage polarization

However, this has not yet translated into an established probiotic therapy for IPF.

Can Probiotics Influence Fibroblasts?

Potentially—but indirectly.

Fibroblasts are unlikely to be affected because probiotic bacteria reach lung tissue.

Instead, microbial metabolites may influence pathways such as:

• TGF-β

• Smad2/3

• PI3K/AKT

• mTOR

• NF-κB

• oxidative stress pathways

The LP03 study is a good example because the probiotic was associated with increased PEA, which then influenced TGF-β/Smad signaling. (PubMed⁠)

This reinforces the importance of metabolomics in future probiotic trials.

What About Akkermansia?

Akkermansia muciniphila has received substantial interest in microbiome research because of associations with:

• metabolic health

• mucus layer function

• intestinal-barrier biology

LP03 increased Akkermansia in the experimental pulmonary fibrosis study.

However, this does not mean that commercially taking Akkermansia will treat pulmonary fibrosis.

No human trial has established this.

What About Bifidobacterium?

Some experimental pulmonary fibrosis research has implicated Bifidobacterium and other organisms as potentially protective microbial components.

In the murine microbiome-transfer experiment, the microbiome associated with less fibrosis had greater abundance of Bifidobacterium and Lactobacilli. (PubMed⁠)

Again, this demonstrates an ecological association.

It does not identify a validated human IPF probiotic prescription.

Probiotics Are Not Interchangeable

One of the biggest mistakes in translating microbiome science into functional medicine is assuming:

beneficial genus = beneficial supplement.

Microbial effects may differ at the:

• species level

• strain level

and sometimes according to the host.

Therefore:

Lactobacillus rhamnosus is not identical to Lactiplantibacillus plantarum.

One Bifidobacterium longum strain is not necessarily identical to another.

The appropriate scientific unit in probiotic research is often the specific strain, not just the genus.

Is There Human Evidence That Probiotics Treat IPF?

At present, adequate randomized controlled human evidence demonstrating disease-modifying efficacy is lacking.

There is no established probiotic shown to produce clinically meaningful improvement in:

• FVC decline

• DLCO

• HRCT fibrosis

• hospitalization

• transplant-free survival

• overall survival

For this reason, probiotics should not currently be described as an antifibrotic treatment.

Can Probiotics Be Used Alongside Antifibrotic Therapy?

Patients may use probiotics for separate gastrointestinal reasons.

However, a person taking:

• nintedanib

• pirfenidone

• immunomodulators

should not assume a probiotic is automatically appropriate.

The clinical context matters.

For example, nintedanib commonly causes diarrhea.

Patients with systemic sclerosis may have:

• dysmotility

• SIBO

• severe bloating

Some individuals may tolerate probiotics poorly.

A personalized approach is preferable.

Probiotics in Autoimmune-Associated ILD

The microbiome may be especially relevant in autoimmune ILD.

Dysbiosis has been reported in:

• systemic sclerosis

• rheumatoid arthritis

• inflammatory myopathies

But there is still no probiotic proven to modify ILD progression in these diseases.

GI symptom improvement and pulmonary disease modification should be considered separate outcomes.

Are Probiotics Safe?

For most immunocompetent adults, conventional probiotics are generally well tolerated.

But caution may be appropriate in:

• severe immunosuppression

• critical illness

• central venous catheter use

• major intestinal barrier disruption

Rare cases of probiotic-associated bloodstream infection have been described in vulnerable populations.

Therefore, “natural” does not mean completely risk-free.

What About Multi-Strain Probiotic Products?

More strains do not necessarily mean greater benefit.

A 20-strain formulation is not automatically superior to a precisely studied single strain.

In pulmonary fibrosis, there is currently no validated multi-strain formulation.

The future may instead involve targeted consortia chosen according to:

• microbial function

• metabolic output

• patient phenotype

Probiotics Versus Prebiotics

Probiotics provide microorganisms.

Prebiotics provide substrates that selectively support microbial activity.

Examples include certain fermentable fibers.

The combination is sometimes called a synbiotic.

For gut–lung biology, supporting existing beneficial organisms through diet may eventually be as important as adding new organisms.

Probiotics Versus Postbiotics

Postbiotics may include:

• microbial metabolites

• microbial components

• inactivated microorganisms

For pulmonary fibrosis, postbiotics are especially interesting because researchers may eventually identify the precise metabolite responsible for a protective effect.

The LP03–PEA finding illustrates this possibility. (PubMed⁠)

Rather than asking:

Which probiotic should we give?

future research may ask:

Which microbial molecule should we target?

Functional and Integrative Medicine Perspective

Functional and integrative medicine can contribute constructively to this field when evidence boundaries remain clear.

A comprehensive approach may assess:

• diet

• bowel symptoms

• reflux

• medication effects

• nutritional status

• SIBO when clinically suspected

• metabolic health

Probiotics may sometimes form part of gastrointestinal care.

But they should not be sold as a way to reverse lung scarring.

The goal should be:

supporting overall gastrointestinal and metabolic health while continuing evidence-based pulmonary care.

What We Know

We know that:

• the gut microbiome can influence pulmonary immunity

• intestinal dysbiosis occurs in pulmonary fibrosis models

• gut microbial composition is associated with severity in human IPF

• microbiome transfer can alter fibrosis severity in mice

• selected probiotics can reduce experimental pulmonary fibrosis

• microbial metabolites may mediate these effects

• LP03 produced significant antifibrotic effects in a 2025 mouse study

(PubMed⁠)

What We Do Not Know

We do not know:

• whether probiotics prevent human IPF progression

• which strain would be optimal

• which patients might respond

• what dose would be required

• how long treatment should continue

• whether probiotics interact meaningfully with antifibrotics

• whether microbiome changes translate into better survival

What Would a Good Human Trial Look Like?

A rigorous trial should use a clearly identified probiotic strain or microbial consortium.

It should evaluate:

• baseline microbiome

• metabolomics

• FVC

• DLCO

• HRCT

• symptoms

• adverse effects

• disease progression

• treatment interaction

Most importantly, changing stool bacteria would not be enough.

A genuine pulmonary treatment would need to improve meaningful lung outcomes.

Frequently Asked Questions

What is the best probiotic for pulmonary fibrosis?

No probiotic has been established as the best probiotic for IPF or pulmonary fibrosis.

Can probiotics reverse lung fibrosis?

There is no human clinical evidence that probiotics reverse established lung fibrosis.

Do probiotics reduce inflammation in the lungs?

Selected probiotics can modify immune responses and have reduced pulmonary inflammation in experimental studies, but results cannot automatically be generalized to human IPF.

Can probiotics increase butyrate?

Certain microbial ecosystems can support SCFA production, but probiotic supplementation does not reliably guarantee increased butyrate.

Should everyone with IPF take probiotics?

No. Probiotic use should depend on the individual gastrointestinal and clinical context.

Conclusion

The relationship between probiotics and pulmonary fibrosis is one of the most interesting emerging areas within gut–lung research.

Experimental evidence increasingly demonstrates that manipulation of intestinal microbiota can alter the severity of lung fibrosis.

The 2025 LP03 study is particularly important because it linked probiotic treatment with:

• changes in the gut microbiome

• increased systemic PEA

• reduced TGF-β/Smad signaling

• reduced collagen deposition and experimental fibrosis

(PubMed⁠)

Other experiments demonstrate that transferring different intestinal microbial ecosystems between mice can alter fibrosis severity, providing evidence that the microbiome itself can influence the phenotype. (PubMed⁠)

At the same time, human research now shows that intestinal microbial composition is associated with IPF severity and transplant-free survival. (PubMed⁠)

Together, these findings provide strong biological justification for studying probiotics.

But they do not establish probiotics as a treatment for human pulmonary fibrosis.

No probiotic has yet been proven to slow FVC decline, reverse fibrosis or improve survival in IPF.

The most promising future direction may therefore be more precise than conventional probiotic supplementation.

Researchers may ultimately identify:

• specific strains

• microbial consortia

• postbiotics

• microbial metabolites

that target defined pathways in selected patients.

Until then, probiotics should be viewed as a promising research strategy, not an established antifibrotic therapy.

About Dr. Samar Shadly

Dr. Samar Shadly is a Consultant Pulmonologist and Certified Functional Medicine Practitioner, with advanced subspecialty training in interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and lung transplantation, together with expertise in functional and integrative medicine.

Her approach combines evidence-based pulmonary medicine with a broader assessment of factors that may influence a patient’s overall health, including nutrition, gastrointestinal health, the gut microbiome, metabolic health, lifestyle, and relevant environmental exposures.

A particular focus of her work is the emerging field of Integrative and Functional Pulmonology, especially in pulmonary fibrosis and autoimmune-associated interstitial lung disease. Her goal is to bridge conventional respiratory medicine with scientifically grounded integrative strategies, while clearly distinguishing established clinical evidence from promising but still experimental research.

Living with Pulmonary Fibrosis or Interstitial Lung Disease?

If you are looking for a more comprehensive assessment that combines specialist pulmonary expertise with a functional and integrative perspective, you can explore whether this approach may be appropriate for your individual condition.

To learn more about consultation options or request an assessment, contact us through the consultation page or WhatsApp.

Integrative care is intended to complement—not replace—evidence-based pulmonary treatment and should always be individualized according to the diagnosis and clinical situation.